Molecular determinant of substrate binding and specificity of cytochrome P450 2J2.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
17 12 2020
Historique:
received: 13 10 2020
accepted: 07 12 2020
entrez: 18 12 2020
pubmed: 19 12 2020
medline: 5 5 2021
Statut: epublish

Résumé

Cytochrome P450 2J2 (CYP2J2) is responsible for the epoxidation of endogenous arachidonic acid, and is involved in the metabolism of exogenous drugs. To date, no crystal structure of CYP2J2 is available, and the proposed structural basis for the substrate recognition and specificity in CYP2J2 varies with the structural models developed using different computational protocols. In this study, we developed a new structural model of CYP2J2, and explored its sensitivity to substrate binding by molecular dynamics simulations of the interactions with chemically similar fluorescent probes. Our results showed that the induced-fit binding of these probes led to the preferred active poses ready for the catalysis by CYP2J2. Divergent conformational dynamics of CYP2J2 due to the binding of each probe were observed. However, a stable hydrophobic clamp composed of residues I127, F310, A311, V380, and I487 was identified to restrict any substrate access to the active site of CYP2J2. Molecular docking of a series of compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole, terfenadine, terfenadone, and arachidonic acid to CYP2J2 confirmed the role of those residues in determining substrate binding and specificity of CYP2J2. In addition to the flexibility of CYP2J2, the present work also identified other factors such as electrostatic potential in the vicinity of the active site, and substrate strain energy and property that have implications for the interpretation of CYP2J2 metabolism.

Identifiants

pubmed: 33335233
doi: 10.1038/s41598-020-79284-0
pii: 10.1038/s41598-020-79284-0
pmc: PMC7746748
doi:

Substances chimiques

Butyrophenones 0
CYP2J2 protein, human 0
Cytochrome P-450 Enzyme Inhibitors 0
Piperidines 0
Arachidonic Acid 27YG812J1I
Astemizole 7HU6337315
Cytochrome P-450 Enzyme System 9035-51-2
Cytochrome P-450 CYP2J2 EC 1.14.14.1
ebastine TQD7Q784P1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

22267

Subventions

Organisme : NIGMS NIH HHS
ID : SC1 GM121275
Pays : United States

Références

BMC Bioinformatics. 2014 Dec 10;15:399
pubmed: 25491031
Bioinformatics. 2006 Nov 1;22(21):2695-6
pubmed: 16940322
Proteins. 2008 May 1;71(2):938-49
pubmed: 18004755
Biochemistry. 2012 Sep 18;51(37):7225-38
pubmed: 22909231
Biotechnol Appl Biochem. 2018 Jan;65(1):46-53
pubmed: 28926141
Trends Biochem Sci. 2010 Oct;35(10):539-46
pubmed: 20541943
J Inorg Biochem. 2018 Jun;183:117-136
pubmed: 29653695
Int J Mol Sci. 2018 Jun 29;19(7):
pubmed: 29966295
Curr Drug Metab. 2014;15(5):502-13
pubmed: 25204827
Curr Protoc Bioinformatics. 2016 Jun 20;54:5.6.1-5.6.37
pubmed: 27322406
J Chem Inf Model. 2013 Jun 24;53(6):1350-7
pubmed: 23647230
J Biol Chem. 2004 Mar 5;279(10):9497-503
pubmed: 14676196
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570
Drug Metab Dispos. 2002 Nov;30(11):1240-5
pubmed: 12386130
Annu Rev Biophys Biomol Struct. 2000;29:291-325
pubmed: 10940251
Int J Mol Sci. 2018 Jul 16;19(7):
pubmed: 30012976
Int J Mol Sci. 2017 Mar 13;18(3):
pubmed: 28335386
Chem Rev. 2005 Jun;105(6):2253-77
pubmed: 15941214
Drug Metab Dispos. 2006 Nov;34(11):1793-7
pubmed: 16896065
J Comput Chem. 2010 Mar;31(4):671-90
pubmed: 19575467
Drug Metab Dispos. 2018 Aug;46(8):1053-1065
pubmed: 29695613
J Mol Biol. 1995 Sep 29;252(4):492-503
pubmed: 7563068
Drug Metab Dispos. 2010 Feb;38(2):347-56
pubmed: 19923256
Proc Natl Acad Sci U S A. 2017 Jan 17;114(3):486-491
pubmed: 28031486
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
J Mol Graph Model. 2011 Nov;31:41-56
pubmed: 21893421
Nature. 2003 Jul 24;424(6947):464-8
pubmed: 12861225
Phys Rev A Gen Phys. 1985 Mar;31(3):1695-1697
pubmed: 9895674
J Chem Theory Comput. 2016 Jan 12;12(1):405-13
pubmed: 26631602
Int J Biol Macromol. 2020 Dec 1;164:510-517
pubmed: 32698066
J Biol Chem. 2006 Mar 17;281(11):7614-22
pubmed: 16352597
Nat Protoc. 2016 May;11(5):905-19
pubmed: 27077332
Philos Trans R Soc Lond B Biol Sci. 2013 Jan 06;368(1612):20120434
pubmed: 23297356
Bioinformatics. 2011 Dec 1;27(23):3276-85
pubmed: 21967761
J Med Chem. 2019 Mar 28;62(6):3036-3050
pubmed: 30807144
Drug Metab Pharmacokinet. 2018 Feb;33(1):61-66
pubmed: 29223463
Antimicrob Agents Chemother. 2013 Nov;57(11):5448-56
pubmed: 23959307
J Biol Chem. 1996 Feb 16;271(7):3460-8
pubmed: 8631948
BMC Bioinformatics. 2006 Jun 22;7:316
pubmed: 16792811
J Comput Chem. 2009 Jul 30;30(10):1545-614
pubmed: 19444816
J Comput Chem. 2008 Aug;29(11):1859-65
pubmed: 18351591
Biochemistry. 2007 Sep 11;46(36):10237-47
pubmed: 17705402
J Comput Chem. 2004 Jan 30;25(2):265-84
pubmed: 14648625
Angew Chem Int Ed Engl. 2017 Oct 9;56(42):13011-13015
pubmed: 28815830
J Am Chem Soc. 2019 Jan 16;141(2):1126-1134
pubmed: 30525564
J Mol Model. 2016 Nov;22(11):279
pubmed: 27796781
J Inorg Biochem. 2015 Jan;142:47-53
pubmed: 25450017
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10037-41
pubmed: 11517324
Biochem Pharmacol. 2016 May 1;107:67-80
pubmed: 26972388
Proc Natl Acad Sci U S A. 1998 May 26;95(11):5942-9
pubmed: 9600896
Pharmacogenet Genomics. 2005 Feb;15(2):105-13
pubmed: 15861034
J Phys Chem Lett. 2020 Feb 20;11(4):1189-1193
pubmed: 31986051
Lancet. 2002 Oct 12;360(9340):1155-62
pubmed: 12387968
Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13682-7
pubmed: 16954191
Drug Metab Pharmacokinet. 2018 Jun;33(3):159-163
pubmed: 29759885
Drug Metab Dispos. 2013 Dec;41(12):2087-94
pubmed: 24021950
Nucleic Acids Res. 2019 Jul 2;47(W1):W636-W641
pubmed: 30976793
Pharmacol Ther. 2020 Nov;215:107601
pubmed: 32534953
Nat Struct Mol Biol. 2005 Sep;12(9):822-3
pubmed: 16086027
Structure. 2009 Apr 15;17(4):489-98
pubmed: 19368882
Int J Mol Sci. 2018 May 30;19(6):
pubmed: 29848998
Trends Pharmacol Sci. 2016 Aug;37(8):625-640
pubmed: 27267697
J Chem Inf Model. 2014 Jul 28;54(7):1951-62
pubmed: 24850022
Proteins. 1999 Sep 1;36(4):419-24
pubmed: 10450083
J Biol Chem. 2006 Mar 3;281(9):5973-81
pubmed: 16373351
Drug Metab Dispos. 2015 Aug;43(8):1250-3
pubmed: 26048912
Acc Chem Res. 2000 Dec;33(12):889-97
pubmed: 11123888
J Chem Theory Comput. 2010 Feb 9;6(2):459-66
pubmed: 26617301
Nat Methods. 2017 Jan;14(1):71-73
pubmed: 27819658
Future Med Chem. 2010 Sep;2(9):1451-68
pubmed: 21103389

Auteurs

Liang Xu (L)

Department of Physics and Astronomy, University of Texas at San Antonio, One UTSA Circle, San Antonio, TX, 78249, USA. liang.xu@utsa.edu.

Liao Y Chen (LY)

Department of Physics and Astronomy, University of Texas at San Antonio, One UTSA Circle, San Antonio, TX, 78249, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH